Boston Scientific Corp BSX has been praised consistently for its
strong growth and
financial performance. Having seen a 40.5% rise over the year and all-time peak at 107.2 USD, the constant surge of the stock has attributed to its recognition as
Massachusetts' most valuable public company. Many experts suggest investing in Boston Scientific, notching it among the
best Medical Device stocks and
low volatility stocks to own currently. Its
inclusion in the Russell 3000E Growth Index also suggests sustained value and innovation. Despite complaints about uncertain fundamentals, the future is deemed optimistic, with sales predicted to grow by 17%. Leading officials, including the CFO and CEO, will disclose the
Full Financial Results of Q2 2025 on July 23. Meanwhile, the company experiences corporate changes as
CFO Dan Brennan announces his retirement. Some might have soured on their outlook due to the company halting the sales of ACURATE TAVR, citing regulatory burden, and listing the 24-acre Minnetonka campus for sale ahead of their Maple Grove move. Such actions, however, do not overshadow the company's
strong sales growth and ambitious plans.
Boston Scientific Corp BSX News Analytics from Mon, 04 Nov 2024 08:00:00 GMT to Sat, 05 Jul 2025 22:04:41 GMT -
Rating 8
- Innovation 7
- Information 8
- Rumor -6
